Huberman LabDiet & Nutrition for Mental Health | Dr. Chris Palmer
CHAPTERS
- 0:00 – 13:00
Introduction: Metabolism Meets Mental Health
Andrew Huberman introduces Dr. Chris Palmer as a Harvard psychiatrist leading a paradigm shift: linking metabolic disorders and mitochondrial dysfunction to psychiatric illnesses. He frames the episode around how nutrition—especially ketogenic diets and fasting—can causally influence mental health, not just weight, across conditions like depression, OCD, ADHD, anxiety, psychosis, and obesity.
- •Dr. Palmer specializes in the relationship between metabolism and psychiatric disorders at Harvard Medical School.
- •He treats psychosis, schizophrenia, ADHD, OCD, anxiety, depression, and more with both medications and nutritional interventions.
- •Ketogenic and modified ketogenic diets, as well as carb reduction and fasting, can change mitochondrial function and mental state.
- •Ketogenic diets were originally developed for epilepsy treatment, not weight loss.
- •Palmer’s book 'Brain Energy' argues for a unified mitochondrial-metabolic model of mental illness.
- 13:00 – 34:00
Dr. Palmer’s Personal Journey: From OCD and Metabolic Syndrome to Low-Carb
Palmer recounts his childhood OCD, family trauma, homelessness, depression, suicidality, and years of unhelpful psychotherapies and medications. In residency at Harvard, he developed metabolic syndrome despite following mainstream low-fat advice, then reversed his metabolic and mental symptoms with an Atkins-style low-carb diet.
- •Childhood OCD, maternal psychosis, homelessness, and later depression and suicidality shaped Palmer’s interest in psychiatry.
- •By his 20s, he had high blood pressure, dyslipidemia, and prediabetes despite low-fat diet and regular exercise.
- •His physician attributed it to 'bad genes' and pushed multiple medications.
- •Skeptical but desperate, Palmer tried a modified Atkins/low-carb diet and within three months normalized all metabolic markers.
- •Unexpectedly, his mood, energy, concentration, and sleep improved dramatically; he woke up rested for the first time in his life.
- •He realized some 'haves vs. have-nots' differences in happiness might be metabolic rather than purely psychological.
- 34:00 – 47:40
Early Clinical Experiments: Low-Carb as an Antidepressant
Seeing his own transformation and similar improvements in family, Palmer cautiously began offering low-carb and ketogenic diets to treatment-resistant depression patients. He found that clinical benefits often appeared only once patients achieved measurable ketosis, prompting more systematic use despite fears of being seen as fringe.
- •Friends and family who adopted his low-carb approach reported better mood, energy, and sleep.
- •As a young attending psychiatrist, Palmer mainly saw treatment-resistant cases (multiple meds, decades of therapy, ECT).
- •He started suggesting Atkins-style diets and used urine ketone strips to check compliance.
- •He observed that antidepressant effects correlated with presence of ketones; without ketosis, many saw little change.
- •A patient with chronic depression became hypomanic after one month in ketosis, underscoring its strong antidepressant power.
- •Due to limited safety/efficacy data at the time, he kept this work low-profile while continuing to refine his approach.
- 47:40 – 59:00
Designing and Titrating Ketogenic Diets in Practice
Palmer explains how he initially 'winged' dietary protocols and then evolved to more structured ketogenic prescriptions, including blood ketone monitoring. He differentiates between using diet as a lifestyle tweak versus a serious brain treatment, and discusses fasting, fat-fasts, and target ketone ranges for different conditions.
- •Early on he used basic Atkins guidelines plus urine ketone strips; later, blood ketone meters for precision.
- •Clinical benefits in mood often appeared only after entering measurable ketosis.
- •Overweight/obese patients typically reach ketosis more easily because of abundant body fat stores.
- •He sometimes uses fat-fasts or short-term fasting to accelerate ketosis.
- •Target ranges: ~0.8 mmol blood ketones for depression; ≥1.5 mmol for psychosis or bipolar disorder when used as a brain treatment.
- •He emphasizes that not everyone needs full ketogenic therapy; some benefit from simply removing junk food and sugar.
- 59:00 – 1:13:00
A Landmark Case: Schizoaffective Disorder Remits on Keto
Palmer describes a 33‑year‑old man with schizoaffective disorder, daily hallucinations, and persecutory delusions, unresponsive to 17 medications, who weighed 340 lbs. Seeking weight loss for self-esteem, the patient agreed to a ketogenic diet that unexpectedly transformed his psychiatric state, challenging everything Palmer knew about schizophrenia treatment.
- •Schizoaffective disorder equals full schizophrenia plus full mood episodes, often more severe than schizophrenia alone.
- •The patient had chronic tormenting psychosis and profound social/functional impairment, plus serious medication-induced weight gain.
- •Within two weeks of keto, his mood, energy, and engagement improved; no medication changes were made.
- •Within 6–8 weeks, his hallucinations diminished and he began questioning his long-held delusions, recognizing he likely had schizophrenia.
- •He ultimately lost ~160 lbs, completed a certificate program, performed improv, went out in public without paranoia, and lived independently.
- •Attempts to fully taper long-standing medications have been challenging, underscoring how hard and risky deprescribing can be after decades on psychotropics.
- •The case catalyzed Palmer’s deep dive into ketogenic neuroscience and mitochondrial mechanisms.
- 1:13:00 – 1:22:20
Adherence, Monitoring, and Medication Safety
The discussion turns to practicalities: why ketogenic diets are difficult to maintain, how ketosis offers a unique objective biomarker of adherence, and why medication changes must be slow and supervised to avoid dangerous withdrawal or relapse. Palmer contrasts this with typical prescribing practices where adherence is often assumed rather than verified.
- •True adherence to ketogenic diets is rare without close support; Palmer usually sees patients weekly during initiation.
- •Blood ketone and glucose measurements provide real-time, objective data on compliance and metabolic response.
- •Most psychiatric patients are at least partially noncompliant with medications due to forgetfulness and complex schedules.
- •Abrupt discontinuation of antidepressants or other psych meds can trigger severe rebound depression, suicidality, or psychosis.
- •Palmer insists any medication taper with dietary changes be gradual and clinician-supervised.
- •In serious mental illness, he treats ketogenic diets like epilepsy therapy: medically supervised, measured, and adjusted—not a casual self-help experiment.
- 1:22:20 – 1:34:20
Epilepsy and the Origins of Medical Ketogenic Therapy
Palmer outlines the 100-year history of ketogenic diets as epilepsy treatments, beginning with observations that fasting reduces seizures. The ketogenic diet was invented to mimic the fasting state metabolically without starvation, and later revived when ~30% of epilepsy patients proved resistant to modern anticonvulsant drugs.
- •Since Hippocrates, fasting has been known to reduce seizures, but it’s unsustainable long-term.
- •In 1921, Dr. Russell Wilder at Mayo Clinic created the ketogenic diet specifically to replicate fasting’s antiseizure effects.
- •Early data: ~50% of patients became seizure-free, ~35% had ≥50% seizure reduction.
- •With the rise of anticonvulsant drugs in the 1950s, keto fell out of favor due to pill convenience.
- •Because 30% of epilepsy remains drug-resistant, Johns Hopkins and others resurrected the diet in the 1970s with strong results.
- •Modern epilepsy protocols show roughly a third become seizure-free, a third significantly improve, and a third see little/no benefit (non-adherence vs biology unclear).
- •Extensive neuroscience shows keto alters neurotransmitters (GABA, glutamate, adenosine), calcium signaling, inflammation, gene expression, gut microbiome, and insulin signaling.
- 1:34:20 – 1:53:40
Mitochondria, Mitophagy, and Mitochondrial Biogenesis: The Core Mechanism
The conversation zooms in on mitochondria as central regulators of brain metabolism and mental health. Palmer explains how ketogenic states and fasting induce mitophagy (removing damaged mitochondria) and mitochondrial biogenesis (creating more, healthier mitochondria), and why that likely underlies keto’s broad neurological and psychiatric effects.
- •Mitochondria are not just 'batteries' but the cell’s 'motherboard', allocating resources and orchestrating many processes.
- •They directly support synthesis and release of serotonin, dopamine, glutamate, and acetylcholine, and ATP alone cannot fully replace mitochondrial roles at synapses.
- •Mitochondria regulate steroid hormone production (cortisol, estrogen, testosterone, progesterone), key to stress responses and mood.
- •They heavily influence epigenetics, with mitochondrial signals impacting expression of ~60% of cellular genes.
- •Mitochondria modulate inflammation, turning immune responses on and off, including macrophage phase-switching in wound healing.
- •Mitophagy and autophagy are triggered by fasting or fasting-mimicking conditions, selectively clearing defective cellular components first.
- •Calorie restriction and similar interventions extend lifespan in many species, likely via mitochondrial optimization.
- •Palmer aligns with emerging views that mitochondrial dysfunction is a unifying driver of aging and age-related diseases, including psychiatric conditions.
- 1:53:40 – 2:09:00
Glucose, Ketones, and Brain Fuel: Untangling the Paradox
Huberman raises a core paradox: neurons 'love' glucose, yet many patients seem to think, feel, and function better when glucose is lowered and ketones are elevated. Palmer argues that high glucose is often a symptom of underlying mitochondrial dysregulation and that ketones preferentially rescue metabolically impaired cells, enabling repair.
- •Certain brain regions show glucose hypometabolism in depression, schizophrenia, and especially Alzheimer’s disease.
- •Some neurons and brain regions need glucose and cannot run solely on ketones; gluconeogenesis remains essential in ketogenic states.
- •Palmer sees elevated glucose as a marker of metabolic dysfunction, often rooted in mitochondrial problems, rather than a primary cause.
- •Metabolically healthy neurons may continue to primarily use glucose even when ketones are present.
- •Metabolically compromised neurons signal distress and may preferentially take up ketones, restoring ATP levels and enabling maintenance/repair.
- •In Alzheimer’s imaging, hypometabolism is region-specific, corresponding with atrophy patterns; ketones partially normalize metabolism in those regions.
- •Palmer stresses that ketogenic diets can be therapeutic even when poor diet was not the original cause (e.g., breastfed infants with epilepsy).
- 2:09:00 – 2:26:00
Alcohol Use Disorder, Ketosis, and Addiction Metabolism
Palmer discusses NIH research showing ketogenic diets can help treat alcoholism by correcting reward-circuit energy deficits. However, he cautions that ketosis may dramatically increase blood alcohol levels upon relapse, raising safety concerns. He also notes that THC directly impairs mitochondrial function via CB1 receptors.
- •Nora Volkow’s lab shows that in alcoholics, reward pathways are metabolically compromised and rely more on acetate (from alcohol) than glucose.
- •A pilot randomized trial in an inpatient detox unit compared keto vs standard diet; both groups got the same detox meds.
- •Keto group needed fewer benzodiazepines, had fewer withdrawal symptoms, fewer cravings, better brain metabolism, and less neuroinflammation.
- •In rats, those on keto who were given the same dose of alcohol had fivefold higher blood alcohol levels than controls.
- •Palmer warns alcoholics on keto: relapse at previous drinking amounts could be lethal or lead to extreme intoxication and accidents.
- •THC impairs mitochondrial function via CB1 receptors on mitochondria, contributing to brain atrophy in heavy-using adolescents and to memory and motivation issues.
- •He emphasizes that while marijuana’s subjective effects (relaxation, spacing out) may be desired, chronic use likely harms brain mitochondrial health.
- 2:26:00 – 2:49:00
Alzheimer’s Disease and Cognitive Decline: Early Keto Trials and Obstacles
The discussion shifts to Alzheimer’s disease, where brain glucose hypometabolism is well documented. Small randomized trials suggest ketogenic or lower-carb diets can improve daily functioning and quality of life, and ketone supplements can normalize regional brain metabolism. But large trials are hampered by adherence challenges, especially in cognitively impaired patients.
- •A small crossover RCT (~26 subjects) found that ketosis improved activities of daily living and quality of life in Alzheimer’s patients; cognitive gains trended positive but didn’t reach significance.
- •Other pilot studies show keto or carb-restricted diets improve Alzheimer’s-related biomarkers compared to low-fat or AHA diets.
- •Stephen Cunnane’s work: ketone esters/salts in non-keto patients acutely improve brain metabolism in hypometabolic regions (PET imaging).
- •In a nursing-home trial, just lowering carbs at breakfast and lunch (with normal dinner) improved cognition, suggesting timing and moderate restriction matter.
- •Johns Hopkins attempted a larger keto trial: screened ~1,300 people but only enrolled 27; adherence issues left only 14 completers.
- •Palmer argues Alzheimer’s keto trials need intensive support: family education, meal provision, and frequent follow-up, mirroring epilepsy protocols.
- •He rejects conspiracy theories about pharma blocking diet trials, pointing instead to logistical and design challenges together with funding priorities.
- 2:49:00 – 3:09:00
Designing 'Doses' of Diet: Protocols, Fasting, and Individualization
Palmer outlines how he customizes dietary 'doses' much like medication. He contrasts approaches for obese vs lean patients, explains when he layers in intermittent or prolonged fasting, and describes monitoring strategies and target ketone ranges. Huberman adds practical questions about timing carbs to support both alertness and sleep.
- •No one-size-fits-all: diet choice depends on diagnosis, severity, metabolic status, and patient willingness.
- •For obesity plus psychiatric illness: strict carb restriction (<20g/day), liberal protein and non-starchy vegetables, fats to satiety but not pushed, leveraging body-fat stores for fuel.
- •For lean patients: same carb limits but active encouragement of high-fat foods (olive oil, avocados, nuts, heavy cream) to avoid malnutrition.
- •He supports vegetarian/vegan ketogenic variants where patients prefer them; it’s about physiology (ketosis), not ideology (meat vs plants).
- •He uses intermittent fasting and occasional 3–7 day water fasts (with black coffee/tea) selectively, especially in type 2 diabetics, to normalize blood sugar.
- •Huberman notes that fasted states can feel rewarding and enhance clarity; Palmer warns of hypomania as a potential risk, manageable with sleep interventions.
- •For mild burnout/anxiety in otherwise healthy people, Palmer often starts with junk food elimination and moderate carb reduction rather than full keto.
- 3:09:00 – 3:27:00
Sleep, Hypomania, and Managing Side Effects of Keto
They examine a key side effect: keto-induced hypomania characterized by reduced sleep need, elevated mood, and high productivity, which can become unhealthy and destabilizing. Palmer describes behavioral, nutritional, and pharmacologic tools to restore adequate sleep while preserving keto’s benefits, especially in bipolar-spectrum patients.
- •Hypomania from keto can show up as feeling amazing on 2–4 hours of sleep, increased activity, and creativity, often welcomed at first.
- •Palmer describes a mental health professional who ran 10–20 miles at 4 a.m. daily on ~3 hours of sleep for six months, losing so much weight he had to stop.
- •First-line intervention: education—at least 6 hours of sleep is non-negotiable for health.
- •Behavioral tools: fixed sleep schedule, staying in bed despite early waking until sleep is re-established for 3–7 nights to break the cycle.
- •Supplements: melatonin and magnesium are common first choices; some patients benefit from adding carbs at dinner or before bed (for non-serious conditions).
- •In serious psychiatric cases where maintaining ketosis is crucial, he avoids bedtime carbs and instead uses short-term benzodiazepines or 'Z‑drugs' to re-establish sleep, then tapers off.
- •He avoids trazodone in hypomanic patients because it’s an antidepressant and could worsen mood elevation.
- 3:27:00 – 3:44:00
Hormones, Fertility, and Sex Differences on Keto
Palmer addresses how ketogenic diets interact with endocrine function and fertility. Data and clinical observations show mixed, sometimes opposite effects in men and women, particularly around female fertility and menstrual cycles, highlighting the need for more research and cautious, individualized use.
- •Mitochondria carry 37 genes via maternal inheritance, but >1,000 mitochondrial-related proteins are coded in nuclear DNA from both parents, so mothers are not solely 'to blame'.
- •Common observation: in couples dieting together, men often do better on keto than women in terms of tolerability and benefits.
- •Animal models show female mice on keto often do not get pregnant, whereas controls reproduce normally.
- •From an evolutionary lens, a 'fasting-mimicking' state might signal energy scarcity, downregulating female fertility to avoid pregnancy during starvation.
- •Palmer also knows cases where keto restored fertility in previously infertile women, as well as women whose serious mental illness remitted on keto.
- •Data on male hormones under keto are limited; obese men may see improved testosterone with weight loss, while underfed lean men could see declines.
- •He concludes that keto’s hormonal effects are highly individual and not yet well mapped; rigorous, sex-specific trials are needed.
- 3:44:00 – 4:04:00
Obesity, GLP‑1 Drugs, and the Limits of Symptom-Only Approaches
In closing, Palmer situates obesity and GLP‑1 agonists (e.g., semaglutide) within his mitochondrial framework. He warns that while new drugs may assist with weight loss, they likely do not resolve the upstream mitochondrial dysfunction driving both obesity and many mental disorders, and could repeat past patterns of short-term wins and long-term disappointments.
- •A major obesity conference recently concluded: 'We don’t know what causes obesity' at the population level.
- •Junk food existed in the 1970s, yet obesity rates have exploded only more recently, suggesting additional environmental or epigenetic factors.
- •Palmer believes brain mitochondrial dysfunction in appetite/metabolism centers is central: damaged circuits fail to regulate intake and energy expenditure.
- •Environmental contributors likely include ultra-processed food, toxins, chronic stress, degraded sleep, light exposure, and perhaps in‑utero influences.
- •He views obesity as a symptom of underlying metabolic derangement, not merely 'too many calories.'
- •GLP‑1 drugs (semaglutide, etc.) produce impressive short-term weight loss but probably do not fix mitochondrial dysfunction.
- •History (Fen‑Phen, amphetamine diet pills, high-dose insulin for type 2 diabetes) shows that focusing on symptom suppression with single molecules often backfires long term.
- •He hopes lifestyle and mitochondrial-targeted interventions (diet, fasting, sleep, exercise, sunlight) will take center stage in both metabolic and mental health treatment.
- 4:04:00
Conclusion: A Mitochondrial Model for Mental Health
Huberman thanks Palmer for pioneering work that reframes mental illness as largely metabolic and mitochondrial. They reiterate that dietary interventions are not meant to replace medication wholesale but to expand the toolkit of evidence-based brain treatments. Palmer encourages rigorous trials and medically supervised implementation, especially for severe conditions.
- •Palmer’s 'Brain Energy' model unifies disparate findings in psychiatry under mitochondrial dysfunction and metabolic dysregulation.
- •Ketogenic and low-carb diets, fasting, and lifestyle interventions can be powerful adjuncts or, in some cases, primary treatments.
- •Case reports and small studies across epilepsy, depression, bipolar disorder, schizophrenia, alcoholism, and Alzheimer’s are promising but require larger RCTs.
- •Huberman underscores that major psychiatric and neurological insights have often emerged from single, carefully studied cases.
- •They both stress: no one should abruptly stop psychiatric meds for a diet experiment; changes should be supervised and gradual.
- •Palmer invites clinicians and researchers to treat diet as a serious, measurable medical intervention, not an afterthought.
- •The episode ends with resources for learning more (Palmer’s website and book, Huberman Lab newsletter) and a broader call to integrate science-based lifestyle tools into mental healthcare.
